Arch Biopartners Inc. (ACHFF)
OTCMKTS · Delayed Price · Currency is USD
0.3161
0.00 (0.00%)
At close: May 26, 2026
Arch Biopartners Revenue
Arch Biopartners had revenue of 158.08K CAD in the twelve months ending December 31, 2025, down -91.86% year-over-year. In the fiscal year ending September 30, 2025, Arch Biopartners had annual revenue of 275.94K, down -87.00%.
Revenue (ttm)
158.08K CAD
Revenue Growth
-91.86%
P/S Ratio
186.26
Revenue / Employee
n/a
Employees
n/a
Market Cap
21.47M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 275.94K | -1.85M | -87.00% |
| Sep 30, 2024 | 2.12M | 138.21K | 6.97% |
| Sep 30, 2023 | 1.98M | 1.02M | 105.63% |
| Sep 30, 2022 | 964.68K | -2.92M | -75.18% |
| Sep 30, 2021 | 3.89M | 3.82M | 5,625.22% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionArch Biopartners News
- 5 days ago - Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial - GlobeNewsWire
- 27 days ago - Royal Columbian Hospital begins patient recruitment in Arch Biopartners' Phase II trial of LSALT peptide targeting CS-AKI - GlobeNewsWire
- 7 weeks ago - Arch Biopartners Closes Non-Brokered Private Placement - GlobeNewsWire
- 2 months ago - Arch Biopartners Arranges Non-Brokered Private Placement - GlobeNewsWire
- 2 months ago - Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial - GlobeNewsWire
- 2 months ago - Arch Biopartners Announces St. Michael's Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide - GlobeNewsWire
- 3 months ago - Arch Biopartners publishes data linking cytokine IL-32 to inflammation, DKD - TheFly
- 3 months ago - Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease - GlobeNewsWire